We just received data on a new analyst forecast for $ZS. RBC Capital gave a rating of 'Outperform' for $ZS.
$ZS Analyst Ratings
Wall Street analysts have issued reports on $ZS in the last several months. We have seen 24 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 10/02/2025
- JP Morgan issued a "Overweight" rating on 09/03/2025
- Needham issued a "Buy" rating on 09/03/2025
- Rosenblatt issued a "Buy" rating on 09/03/2025
- Barclays issued a "Overweight" rating on 09/03/2025
- Wedbush issued a "Outperform" rating on 09/03/2025
- Baird issued a "Outperform" rating on 09/03/2025
To track analyst ratings and price targets for $ZS, check out Quiver Quantitative's $ZS forecast page.
$ZS Price Targets
Multiple analysts have issued price targets for $ZS recently. We have seen 29 analysts offer price targets for $ZS in the last 6 months, with a median target of $330.0.
Here are some recent targets:
- Matthew Hedberg from RBC Capital set a target price of $350.0 on 10/02/2025
- Kingsley Crane from Canaccord Genuity set a target price of $340.0 on 09/04/2025
- Trevor Walsh from JMP Securities set a target price of $355.0 on 09/03/2025
- Catharine Trebnick from Rosenblatt set a target price of $330.0 on 09/03/2025
- Mike Cikos from Needham set a target price of $350.0 on 09/03/2025
- Keith Bachman from BMO Capital set a target price of $315.0 on 09/03/2025
- Roger Boyd from UBS set a target price of $350.0 on 09/03/2025
$ZS Insider Trading Activity
$ZS insiders have traded $ZS stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.
Here’s a breakdown of recent trading of $ZS stock by insiders over the last 6 months:
- AJAY MANGAL has made 0 purchases and 12 sales selling 120,000 shares for an estimated $36,106,497.
- CHARLES H GIANCARLO has made 0 purchases and 8 sales selling 67,824 shares for an estimated $20,416,445.
- SYAM NAIR (CTO) has made 0 purchases and 2 sales selling 33,011 shares for an estimated $8,470,995.
- ADAM GELLER (Chief Product Officer) has made 0 purchases and 9 sales selling 28,328 shares for an estimated $8,153,294.
- MICHAEL J. RICH (CRO and President of WW Sales) has made 0 purchases and 3 sales selling 25,996 shares for an estimated $7,617,249.
- ANDREW WILLIAM FRASER BROWN has made 0 purchases and 2 sales selling 20,333 shares for an estimated $6,033,118.
- ROBERT SCHLOSSMAN (Chief Legal Officer) has made 0 purchases and 8 sales selling 18,804 shares for an estimated $5,417,119.
- RAJ JUDGE (EVP, Corp. Strategy & Ventures) has made 0 purchases and 2 sales selling 7,481 shares for an estimated $2,167,927.
- JAGTAR SINGH CHAUDHRY (CEO & Chairman) has made 0 purchases and 2 sales selling 5,714 shares for an estimated $1,669,445.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZS Hedge Fund Activity
We have seen 522 institutional investors add shares of $ZS stock to their portfolio, and 314 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 1,879,992 shares (+76546.9%) to their portfolio in Q2 2025, for an estimated $590,204,688
- FMR LLC added 1,639,111 shares (+88.0%) to their portfolio in Q2 2025, for an estimated $514,582,507
- NOMURA HOLDINGS INC removed 1,397,481 shares (-99.7%) from their portfolio in Q2 2025, for an estimated $438,725,185
- DEUTSCHE BANK AG\ removed 1,387,512 shares (-76.8%) from their portfolio in Q2 2025, for an estimated $435,595,517
- HSBC HOLDINGS PLC removed 1,332,637 shares (-95.2%) from their portfolio in Q2 2025, for an estimated $418,368,059
- MARSHALL WACE, LLP removed 1,291,369 shares (-89.0%) from their portfolio in Q2 2025, for an estimated $405,412,383
- GOLDMAN SACHS GROUP INC removed 1,289,378 shares (-42.3%) from their portfolio in Q2 2025, for an estimated $404,787,329
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
